MeSH term
Frequency | Condition_Probility | Female | 70 | 0.0 |
Humans | 237 | 0.0 |
Pregnancy | 5 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics/metabolism | 9 | 15.0 |
Receptors, Fibroblast Growth Factor/genetics/metabolism | 5 | 21.0 |
Signal Transduction | 23 | 0.0 |
*Translocation, Genetic | 12 | 1.0 |
Animals | 104 | 0.0 |
Blotting, Western | 15 | 0.0 |
Cattle | 6 | 0.0 |
Cell Nucleus/metabolism | 6 | 0.0 |
Cells, Cultured | 31 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics/*metabolism | 7 | 5.0 |
Receptors, Fibroblast Growth Factor/genetics/*metabolism | 17 | 48.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 24 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 74 | 0.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Transfection | 22 | 0.0 |
Adolescent | 12 | 0.0 |
Adult | 34 | 0.0 |
Aged | 22 | 0.0 |
Child | 12 | 0.0 |
*Gene Expression | 6 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Male | 65 | 0.0 |
Middle Aged | 25 | 0.0 |
Oligonucleotide Array Sequence Analysis | 6 | 0.0 |
Prognosis | 5 | 0.0 |
Research Support, Non-U.S. Gov't | 179 | 0.0 |
Binding Sites | 14 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Cell Division | 17 | 0.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Endothelium, Vascular/*cytology | 2 | 1.0 |
Enzyme Inhibitors/pharmacology | 8 | 0.0 |
Fibroblast Growth Factor 2/*metabolism | 7 | 12.0 |
Genes, Dominant | 5 | 0.0 |
Immunohistochemistry | 23 | 0.0 |
Phosphorylation | 17 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Protein Binding | 19 | 0.0 |
Receptor Protein-Tyrosine Kinases/*chemistry/*metabolism | 2 | 25.0 |
Receptors, Fibroblast Growth Factor/*chemistry/*metabolism | 4 | 100.0 |
Receptors, Vitronectin/metabolism | 2 | 11.0 |
Recombinant Proteins/metabolism | 9 | 0.0 |
Time Factors | 8 | 0.0 |
Acute Disease | 2 | 0.0 |
*Adaptor Proteins, Signal Transducing | 4 | 0.0 |
Case-Control Studies | 3 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Leukemia, Myeloid/*genetics | 2 | 1.0 |
Receptor Protein-Tyrosine Kinases/genetics/physiology | 2 | 20.0 |
Translocation, Genetic | 7 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Fibroblast Growth Factors/genetics | 4 | 10.0 |
Gene Expression | 17 | 0.0 |
Neuregulin-1/genetics | 2 | 28.0 |
Oncogene Proteins, Fusion/genetics | 2 | 2.0 |
Receptor Protein-Tyrosine Kinases/genetics | 10 | 6.0 |
Receptors, Fibroblast Growth Factor/genetics | 8 | 12.0 |
Reverse Transcriptase Polymerase Chain Reaction | 23 | 0.0 |
Transcription Factors/genetics | 6 | 0.0 |
Tumor Cells, Cultured | 29 | 0.0 |
Apoptosis | 2 | 0.0 |
Cell Division/drug effects | 9 | 0.0 |
Kinetics | 7 | 0.0 |
Mice | 61 | 0.0 |
Mice, Nude | 5 | 0.0 |
Receptor Protein-Tyrosine Kinases/antagonists & inhibitors | 2 | 11.0 |
Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors | 2 | 100.0 |
Receptors, Growth Factor/*antagonists & inhibitors | 2 | 11.0 |
Receptors, Vascular Endothelial Growth Factor | 3 | 0.0 |
*Chromosomes, Human, Pair 8 | 19 | 8.0 |
Protein-Tyrosine Kinase/genetics | 2 | 1.0 |
Cell Line | 24 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics/*metabolism | 2 | 14.0 |
Receptors, Fibroblast Growth Factor/*genetics/*metabolism | 7 | 41.0 |
Amino Acid Sequence | 58 | 0.0 |
Comparative Study | 23 | 0.0 |
Gene Expression Regulation, Developmental | 5 | 0.0 |
In Situ Hybridization | 16 | 0.0 |
*MAP Kinase Signaling System | 2 | 1.0 |
Mesoderm/metabolism | 2 | 2.0 |
Molecular Sequence Data | 77 | 0.0 |
Morphogenesis | 2 | 0.0 |
Sequence Alignment | 11 | 0.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
Species Specificity | 3 | 0.0 |
Acrocephalosyndactylia/*genetics/physiopathology | 2 | 100.0 |
*Alternative Splicing | 4 | 0.0 |
Child, Preschool | 12 | 0.0 |
*Exons | 2 | 0.0 |
Phenotype | 17 | 0.0 |
*Point Mutation | 7 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 28 | 7.0 |
Receptors, Fibroblast Growth Factor/*genetics | 46 | 20.0 |
Fibroblast Growth Factor 2/physiology | 2 | 8.0 |
Rats | 20 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/*physiology | 2 | 3.0 |
Receptors, Fibroblast Growth Factor/*physiology | 3 | 33.0 |
Signal Transduction/*physiology | 9 | 0.0 |
Base Sequence | 50 | 0.0 |
Cohort Studies | 3 | 0.0 |
DNA Mutational Analysis | 8 | 0.0 |
Exons/genetics | 2 | 0.0 |
Infant | 9 | 0.0 |
Models, Molecular | 6 | 0.0 |
Mutation/*genetics | 5 | 0.0 |
Pedigree | 15 | 0.0 |
Prospective Studies | 2 | 0.0 |
Protein Structure, Tertiary | 9 | 0.0 |
Receptor Protein-Tyrosine Kinases/chemistry/*genetics | 4 | 23.0 |
Receptors, Fibroblast Growth Factor/chemistry/*genetics | 8 | 61.0 |
Fibroblast Growth Factors/*biosynthesis/genetics | 2 | 20.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
RNA, Messenger/metabolism | 10 | 0.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
Receptors, Fibroblast Growth Factor/*biosynthesis | 4 | 57.0 |
Aged, 80 and over | 5 | 0.0 |
*Protein-Tyrosine Kinase | 26 | 8.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 8 | 3.0 |
Receptors, Fibroblast Growth Factor/*metabolism | 19 | 35.0 |
Tissue Distribution | 5 | 0.0 |
Chromosome Breakage/genetics | 2 | 3.0 |
Chromosomes, Human, Pair 8/*genetics | 9 | 7.0 |
Myeloproliferative Disorders/*genetics | 15 | 51.0 |
Oncogene Proteins/*genetics | 2 | 1.0 |
Oncogene Proteins, Fusion/*genetics | 6 | 3.0 |
*Proto-Oncogene Proteins | 6 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
Translocation, Genetic/*genetics | 4 | 1.0 |
Fibroblast Growth Factors/*genetics | 5 | 10.0 |
Gestational Age | 2 | 0.0 |
RNA, Messenger/analysis | 11 | 0.0 |
Skull/*embryology | 4 | 50.0 |
In Situ Hybridization, Fluorescence | 14 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 4 | 1.0 |
Pyrroles/pharmacology | 4 | 8.0 |
DNA Primers | 9 | 0.0 |
Membrane Proteins/*metabolism | 3 | 0.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/chemistry/genetics/*metabolism | 3 | 13.0 |
Receptors, Fibroblast Growth Factor/chemistry/genetics/*metabolism | 5 | 83.0 |
Binding, Competitive | 3 | 0.0 |
Brain/metabolism | 3 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Fibroblast Growth Factor 1/metabolism | 2 | 28.0 |
Lung/metabolism | 2 | 1.0 |
Receptors, Fibroblast Growth Factor/metabolism | 8 | 17.0 |
Cloning, Molecular | 15 | 0.0 |
Fibroblast Growth Factors/*antagonists & inhibitors | 2 | 66.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Chromosomes, Human, Pair 6/genetics | 2 | 1.0 |
Chromosomes, Human, Pair 8/genetics | 3 | 3.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Isoenzymes/metabolism | 4 | 0.0 |
Leucine/*genetics | 2 | 8.0 |
Mitogen-Activated Protein Kinases/metabolism | 4 | 0.0 |
Phospholipase C/metabolism | 6 | 2.0 |
Trans-Activators/metabolism | 3 | 0.0 |
Translocation, Genetic/genetics | 3 | 3.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Genetic Markers | 3 | 0.0 |
Ligands | 11 | 0.0 |
Mice, Mutant Strains | 4 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics/metabolism | 4 | 6.0 |
Receptors, Fibroblast Growth Factor/*genetics/metabolism | 4 | 18.0 |
Aging/metabolism | 2 | 1.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Fetus/metabolism | 2 | 1.0 |
Mutation | 11 | 0.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 12 | 4.0 |
Blotting, Northern | 9 | 0.0 |
Cell Differentiation | 12 | 0.0 |
Down-Regulation | 3 | 0.0 |
Craniosynostoses/*genetics/radiography | 2 | 50.0 |
English Abstract | 7 | 0.0 |
Syndrome | 13 | 0.0 |
Adenocarcinoma/*pathology | 2 | 2.0 |
Receptors, Fibroblast Growth Factor/genetics/*physiology | 6 | 66.0 |
Retrospective Studies | 5 | 0.0 |
Treatment Outcome | 2 | 0.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Fibroblast Growth Factor 2/*pharmacology | 6 | 5.0 |
Gene Expression/drug effects | 2 | 0.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 2 | 0.0 |
Chromosomes, Human, Pair 12/genetics | 2 | 2.0 |
Chromosomes, Human, Pair 9/genetics | 2 | 1.0 |
Karyotyping | 3 | 0.0 |
*Carrier Proteins | 5 | 0.0 |
Chromosome Mapping | 13 | 0.0 |
Chromosomes, Human, Pair 4/*genetics | 2 | 2.0 |
*Repressor Proteins | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Zinc Fingers/genetics | 2 | 1.0 |
Prostatic Hyperplasia/*metabolism | 2 | 4.0 |
3T3 Cells | 12 | 0.0 |
CHO Cells | 6 | 0.0 |
Hamsters | 6 | 0.0 |
Mutagenesis | 3 | 0.0 |
Protein Structure, Secondary | 5 | 0.0 |
Receptors, Fibroblast Growth Factor/*chemistry | 2 | 100.0 |
Enzyme Activation | 4 | 0.0 |
PC12 Cells | 6 | 1.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Receptors, Fibroblast Growth Factor/genetics/metabolism/*physiology | 2 | 50.0 |
Fibroblast Growth Factors/*physiology | 2 | 10.0 |
Infant, Newborn | 5 | 0.0 |
Receptor Protein-Tyrosine Kinases/physiology | 2 | 4.0 |
Fibroblast Growth Factors/*metabolism | 9 | 22.0 |
Protein Isoforms/metabolism | 3 | 1.0 |
Reference Values | 7 | 0.0 |
Fibroblast Growth Factor 2/*analysis | 2 | 10.0 |
Receptors, Fibroblast Growth Factor/*analysis | 4 | 44.0 |
Cell Differentiation/drug effects | 3 | 0.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
Fibroblast Growth Factor 1 | 6 | 21.0 |
Immunoblotting | 3 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Gene Amplification | 2 | 0.0 |
Gene Deletion | 2 | 0.0 |
Acrocephalosyndactylia/genetics | 6 | 46.0 |
Craniosynostoses/*genetics | 10 | 27.0 |
Cytogenetic Analysis | 2 | 1.0 |
Diagnosis, Differential | 3 | 0.0 |
Fibroblast Growth Factor 2/metabolism | 8 | 8.0 |
Growth Substances/*metabolism | 3 | 2.0 |
Acrocephalosyndactylia/*genetics | 5 | 22.0 |
Amino Acid Substitution | 2 | 0.0 |
Homeodomain Proteins/genetics | 3 | 1.0 |
*Mutation | 9 | 0.0 |
*Nuclear Proteins | 3 | 0.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Receptors, Fibroblast Growth Factor/*genetics/physiology | 3 | 75.0 |
Cell Proliferation/drug effects | 2 | 2.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Phosphotyrosine/metabolism | 5 | 1.0 |
Receptor Protein-Tyrosine Kinases/*genetics/physiology | 2 | 50.0 |
Craniosynostoses/*genetics/physiopathology | 2 | 50.0 |
Genetic Screening | 2 | 0.0 |
Nuclear Proteins/genetics | 4 | 1.0 |
*Transcription Factors | 7 | 0.0 |
Alternative Splicing | 6 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
Protein Isoforms/biosynthesis/genetics | 2 | 3.0 |
Receptors, Fibroblast Growth Factor/*biosynthesis/genetics | 4 | 36.0 |
Disease Progression | 4 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Proteins/*genetics | 2 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
*Signal Transduction | 7 | 0.0 |
*Chromosomes, Human, Pair 19 | 2 | 0.0 |
Cell Differentiation/*physiology | 2 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Nuclear Magnetic Resonance, Biomolecular | 3 | 1.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
Consanguinity | 2 | 0.0 |
Family Health | 3 | 0.0 |
Genotype | 7 | 0.0 |
Achondroplasia/*genetics | 2 | 6.0 |
*Genes, p53 | 2 | 0.0 |
Lung Neoplasms/secondary | 2 | 2.0 |
Chromosomes, Artificial, Yeast | 3 | 0.0 |
*Cell Differentiation | 3 | 1.0 |
Fibroblast Growth Factor 2/pharmacology | 4 | 1.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Fibroblast Growth Factor 1/*metabolism | 4 | 36.0 |
In Vitro | 2 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
Point Mutation/*genetics | 4 | 1.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Fibroblast Growth Factor 2/chemistry/metabolism | 2 | 100.0 |
Point Mutation | 10 | 0.0 |
Protein Isoforms | 3 | 0.0 |
DNA-Binding Proteins/genetics | 4 | 0.0 |
Blotting, Southern | 8 | 0.0 |
*Mutation, Missense | 3 | 0.0 |
Skull/*abnormalities | 2 | 10.0 |
COS Cells | 6 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
*Milk Proteins | 2 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Tyrosine/*metabolism | 2 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Receptors, Fibroblast Growth Factor/biosynthesis/*genetics | 4 | 36.0 |
Macromolecular Substances | 3 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Stem Cells/cytology/drug effects/*metabolism | 2 | 15.0 |
Transgenes | 3 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Breast Neoplasms/*genetics | 4 | 0.0 |
Polymerase Chain Reaction | 18 | 0.0 |
Vascular Endothelial Growth Factor A | 4 | 0.0 |
Vascular Endothelial Growth Factors | 4 | 0.0 |
*Gene Amplification | 6 | 1.0 |
Multivariate Analysis | 3 | 0.0 |
Thymidine/metabolism | 2 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Consensus Sequence | 3 | 0.0 |
Hela Cells | 4 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
src Homology Domains | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/biosynthesis/*genetics | 2 | 10.0 |
Regeneration | 2 | 3.0 |
Chimeric Proteins/metabolism | 3 | 1.0 |
Fibroblast Growth Factors/metabolism | 6 | 11.0 |
Substrate Specificity | 3 | 0.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Cell Division/physiology | 5 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics/*physiology | 3 | 11.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
RNA, Neoplasm/genetics/isolation & purification | 2 | 3.0 |
Hypogonadism/*genetics | 2 | 10.0 |
Kallmann Syndrome/*genetics | 2 | 33.0 |
Brain Neoplasms/*pathology | 3 | 4.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
*Chromosomes, Human, Pair 13 | 5 | 2.0 |
DNA-Binding Proteins/*genetics | 5 | 0.0 |
Dimerization | 4 | 0.0 |
Recombinant Fusion Proteins/genetics | 2 | 1.0 |
Blood Vessels/metabolism | 2 | 7.0 |
Fibroblast Growth Factor 2/genetics/*metabolism | 3 | 21.0 |
*Microtubule-Associated Proteins | 2 | 2.0 |
Multigene Family | 2 | 0.0 |
Cysteine | 2 | 1.0 |
Exons | 11 | 0.0 |
Protein Conformation | 5 | 0.0 |
Receptor Protein-Tyrosine Kinases/analysis/genetics | 2 | 28.0 |
Receptors, Fibroblast Growth Factor/analysis/*genetics | 2 | 66.0 |
Receptor, Platelet-Derived Growth Factor beta | 2 | 11.0 |
*Chromosome Mapping | 2 | 0.0 |
Gene Library | 2 | 0.0 |
Models, Genetic | 3 | 0.0 |
Breast Neoplasms/*genetics/pathology | 2 | 0.0 |
Breast/*metabolism | 2 | 3.0 |
Introns | 5 | 0.0 |
*Receptor Protein-Tyrosine Kinases | 22 | 38.0 |
*Fibroblast Growth Factors | 6 | 6.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Transduction, Genetic | 3 | 0.0 |
Genetic Vectors | 4 | 0.0 |
Neurites/drug effects | 2 | 13.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/analysis | 2 | 4.0 |
Gene Expression Regulation/radiation effects | 2 | 10.0 |
Receptors, Fibroblast Growth Factor/physiology | 4 | 44.0 |
Fibroblast Growth Factor 1/*genetics | 2 | 25.0 |
Zinc Fingers | 3 | 0.0 |
Craniofacial Dysostosis/genetics | 2 | 28.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Calcium/*metabolism | 2 | 0.0 |
Swine | 3 | 0.0 |
Chromosome Deletion | 3 | 0.0 |
Carbohydrate Conformation | 2 | 1.0 |
Genetic Heterogeneity | 3 | 1.0 |
Models, Biological | 2 | 0.0 |
Proteins/physiology | 2 | 1.0 |
Fibroblast Growth Factor 1/genetics/*metabolism | 2 | 50.0 |
Jurkat Cells | 2 | 0.0 |
Fibroblast Growth Factors/pharmacology | 2 | 3.0 |
Conserved Sequence | 2 | 0.0 |
*Neovascularization, Pathologic | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/metabolism | 2 | 1.0 |
Fibroblast Growth Factor 2/*physiology | 2 | 9.0 |
Fibroblast Growth Factors | 2 | 14.0 |
Polymorphism, Genetic | 2 | 0.0 |
Fibroblast Growth Factor 2/*genetics | 2 | 10.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Epithelial Cells | 2 | 0.0 |
Epithelium/chemistry/metabolism | 2 | 12.0 |
Receptors, Fibroblast Growth Factor/*analysis/genetics | 2 | 50.0 |
Digestive System | 2 | 50.0 |
Surface Plasmon Resonance | 2 | 1.0 |
Subcellular Fractions | 2 | 1.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Restriction Mapping | 2 | 0.0 |
*Brain Chemistry | 2 | 1.0 |
Receptors, Fibroblast Growth Factor/analysis | 3 | 18.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/*genetics | 2 | 0.0 |
Heparin/pharmacology | 2 | 0.0 |
Bone Marrow/metabolism | 2 | 1.0 |
Biopsy | 2 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Cell Membrane/chemistry | 3 | 2.0 |
Molecular Weight | 2 | 0.0 |
Cross-Linking Reagents | 3 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
Genome, Human | 2 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
Werner Syndrome/*genetics | 3 | 10.0 |
Xenopus Proteins/genetics | 2 | 28.0 |
Salamandridae/*physiology | 2 | 66.0 |
Chromatography, Affinity | 2 | 0.0 |
Culture Media, Conditioned | 2 | 0.0 |
DNA/biosynthesis | 3 | 0.0 |
Signal Transduction/genetics | 2 | 0.0 |
Abnormalities, Multiple/*genetics | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
*RNA Splicing | 3 | 1.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Lod Score | 2 | 0.0 |
Heparin/*metabolism | 2 | 2.0 |
Receptors, Fibroblast Growth Factor | 4 | 18.0 |
Thermodynamics | 2 | 0.0 |
Umbilical Veins | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Fetus | 2 | 0.0 |
DNA | 2 | 0.0 |
Recombinant Fusion Proteins/*physiology | 2 | 40.0 |
Calcium/metabolism | 2 | 0.0 |
Xenopus laevis | 2 | 0.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
Thyrotropin/pharmacology | 3 | 4.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Gene Dosage | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Endothelial Growth Factors/pharmacology | 2 | 1.0 |
Intercellular Signaling Peptides and Proteins/pharmacology | 2 | 7.0 |
Lymphokines/pharmacology | 2 | 1.0 |
Nucleic Acid Hybridization/*methods | 2 | 4.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |